Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. - Wikidata - awgldk - TriplyDB

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

http://www.wikidata.org/entity/Q33566582

about

Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment Caveolin-1, a stress-related oncotarget, in drug resistance Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).Assessment of drug transporter function using fluorescent cell imaging Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Contribution of tumoral and host solute carriers to clinical drug response.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.Advances in the design and synthesis of prazosin derivatives over the last ten years.The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2 Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.The ABCG family of membrane-associated transporters: you don't have to be big to be mighty Mechanisms of resistance to BCR-ABL kinase inhibitors.Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.The controversial role of ABC transporters in clinical oncology.Selection of therapy: rational decisions based on molecular events.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

P2860

Q24594356-34037AC0-9D27-4945-8129-8D917A01090B Q26766299-B1B83AFA-6714-44D6-8EB0-F7D64490C3C3 Q26782615-D987E953-9A7F-403B-96DA-9B49B5DDE6D1 Q26865927-A7C63C84-3446-4669-8047-B2E268A9D3FD Q27004672-95222E72-DCD5-4BDD-AF98-1CE5BDC42005 Q28067499-37D39D5D-0E80-4CF7-A170-181E8CE4E908 Q30364846-FC9AB6FA-66F8-4EA4-A539-BF916C603249 Q30571452-2E7C07D1-2E1E-4634-BD8F-B8932F7B847C Q33878636-09641F68-0AC6-4C9A-9608-278286AB6B7C Q34176588-51C91F3D-10C0-4D5A-A066-0C30FF3787DB Q34774289-6898EF69-6973-44E3-8B79-DE089D847640 Q34871636-A8BE6068-387B-407A-99DE-1D46F77E21B1 Q35171274-CC13A90F-8165-4C67-A091-D741052FBF72 Q35186322-87008E41-AAA4-454B-8D64-A9061B9481F7 Q35708124-E2BD9B8B-D465-40E6-B505-E2F24FEF3A6D Q35946822-ED26064B-7898-4153-AA2C-0AD97B2BA83D Q35946876-95645E99-34EB-4703-BA58-73D6F3D051C7 Q35991845-78376FA2-7F2A-49EF-9C12-1D928B9C36C5 Q36015358-2EDBA6A8-978B-4FB8-AF38-488D9376F201 Q36442931-F66412F7-0789-4AFA-A812-2166592FC179 Q36557448-4A2FB167-4F95-4233-A7FE-B9AC9162B1A6 Q36827500-34BDA709-B9A0-490E-8319-F6C48AEBA71A Q36933169-94B3E5D9-B483-483C-ACF5-C6E5F9AE88BD Q37087238-9ECC54CA-F931-435B-B7B4-34DEC3044E67 Q37140624-9779C355-B494-4822-91F2-EBA368AFA69B Q37289700-DCC3D9E2-3FEA-45DF-A846-0D83EFC39583 Q37598626-034AABA9-58EF-4277-BFF4-86D435820CFC Q37634419-3670A027-8C84-4C03-8C9D-E9212E307D55 Q37810986-AD1D1632-BC3D-4302-BA9F-111E6235F9BF Q37822832-DAF3C2D3-C347-4064-A2E5-2878CE63C814 Q37836923-DA92BD0D-D616-45B0-ADAB-CD678597E50B Q37853578-744AC369-2AFF-4708-B559-9D38D1706487 Q37862942-A8CDDA8D-16DA-4112-86B7-98958EDA4C57 Q37941758-407B6E64-80A7-42E5-88CB-2EA3603C49F0 Q37952910-F6920FBB-57B4-4D9D-9139-A87EDA94C2E5 Q37958162-9181EB75-0D1F-4162-A697-A4BF108B71B0 Q37960141-C531276C-CCC4-40F4-AFFA-758F890BA24F Q37965564-0536FEA6-4D7D-4A49-AF37-6C6292E8D07A Q38037648-9DB436B6-F961-4A25-96D5-CE7D1109E973 Q38082728-E60E33E8-6CBA-4D9B-8E66-3F07D584D6C0

P2860

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

http://www.wikidata.org/entity/Q33566582

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@ast

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@en

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@nl

type

label

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@ast

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@en

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@nl

prefLabel

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@ast

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@en

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@nl

P1433

Q33566582-E5AA568C-16A3-4E3C-9C46-2BD78F769043

P1476

Q33566582-4B132F5C-4B37-47D0-89D7-078FC8ACE9E4

P2093

Q33566582-17CDE1AF-6314-4E91-A047-3AB58E494F18

Q33566582-230DE0F7-2825-41D9-8E94-0AD9BE06BC12

Q33566582-2CF44C1C-6B39-4ACE-8D51-C7081043C03B

Q33566582-47147A53-958F-41DA-8B59-99AF80398653

Q33566582-666240A2-58EC-4CCA-B2A4-A1CBAEB55C33

Q33566582-6F027097-0D7D-457E-867F-439E207D3D64

Q33566582-8CB52D0D-4EB2-4F27-85FA-C2CE5AB51E42

Q33566582-B1C88C14-A8F7-4386-9172-C993267D2332

Q33566582-BAB6C1DD-0CEB-434A-B730-EA5EA112A908

P2860

Q33566582-00B83318-AFE7-47A6-B18F-6FBE8601FF28

Q33566582-013A7087-7E18-463F-8B17-61DE89FAA88B

Q33566582-0B0E9B31-0C97-4447-B7DE-9181AFC817B4

Q33566582-0BEC6B24-834A-4328-88D8-03EEBD12100A

Q33566582-0C61EBBE-E141-42AC-B914-294A461D2EE3

Q33566582-2660983D-DD25-4B05-8597-B806FCF81359

Q33566582-2C68B929-24CF-48A1-8D3E-24D4EA87CDDE

Q33566582-2E4CD2EE-3098-4150-BE17-FD97EDA19101

Q33566582-2ED59726-A8D1-476B-84D9-70039AB59079

Q33566582-336364E5-E011-4F65-B22F-E1543DF5F975

P304

Q33566582-65389F9F-5B42-4F06-801F-961FB957AF00

P31

Q33566582-304C01D1-0857-4B53-ADAF-D3929E602166

P356

Q33566582-A239AFC1-1C30-435F-A714-81F47201527D

P433

Q33566582-FFE6B3C0-583D-4CD5-A281-3DF016C192AD

P478

Q33566582-649C4B01-CAB5-4895-A81D-721B91FDA89D

P50

Q33566582-4D6F6077-D092-4CC8-91A2-4E5A0E7B8FAF

P577

Q33566582-41B4EE63-3638-4756-9747-C86A1C964D89

P5875

Q33566582-75C5AA06-E5FF-4505-9886-288FEB8A5B10

P698

Q33566582-9DC747A5-72F1-4C37-A2E9-599177FA355D

P932

Q33566582-A6DCA9C5-B4D5-4A22-8BC8-748B0FD4479C

P356

P1433

Drug Metabolism and Disposition

P1476

Comparison of ATP-binding cass ...... nib, nilotinib, and dasatinib.

@en

P2093

Andreas Neubauer

http://www.w3.org/2001/XMLSchema#string

Christian Scharenberg

http://www.w3.org/2001/XMLSchema#string

Cornelia Brendel

http://www.w3.org/2001/XMLSchema#string

John F Deeken

http://www.w3.org/2001/XMLSchema#string

Marius Dohse

http://www.w3.org/2001/XMLSchema#string

Suneet Shukla

http://www.w3.org/2001/XMLSchema#string

Suresh V Ambudkar

http://www.w3.org/2001/XMLSchema#string

Susan E Bates

http://www.w3.org/2001/XMLSchema#string

Thorsten Volkmann

http://www.w3.org/2001/XMLSchema#string

P2860

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux.

ABCG2: determining its relevance in clinical drug resistance.

The mechanism of ATP-dependent multidrug transport by P-glycoprotein.

P304

1371-1380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.109.031302

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43348113

http://www.w3.org/2001/XMLSchema#string

P698

20423956

http://www.w3.org/2001/XMLSchema#string

P932

2913625

http://www.w3.org/2001/XMLSchema#string